依鲁替尼作为高危慢性淋巴细胞白血病移植前的过渡治疗：一例病例报告及文献综述
Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature.
作者信息
Annalisa Arcari, Simona Bassi, Lara Pochintesta, Elena Trabacchi, Filippo Moroni Carlo, Angela Rossi, Luca Zanlari, Daniele Vallisa
机构信息
Hematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
Transfusional Centre and Immunohematology, Immunogenetics Laboratory, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
出版信息
Leuk Res Rep. 2017 Nov 15;8:21-23. doi: 10.1016/j.lrr.2017.11.001. eCollection 2017.
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a "real life" situation.
慢性淋巴细胞白血病（CLL）的治疗格局已受到新型药物类别的挑战，如B细胞受体（BCR）抑制剂和BCL-2拮抗剂。在部分高危患者中，选择开始异基因造血干细胞移植（alloHCT）还是继续使用这些药物存在争议。此外，关于对alloHCT可行性的影响以及给药最佳时机的已发表数据有限。在此，我们展示一例复发的TP53突变型CLL患者，使用依鲁替尼作为alloHCT的过渡治疗，讨论在“现实生活”情况下不同治疗方案的风险和益处。
Zotero 插件